New Two-Drug attack on most severe arthritis type
NCT ID NCT06301373
Summary
This study is testing if a personalized, two-drug treatment works better than the standard single drug for people with a severe type of rheumatoid arthritis (RA). Researchers will enroll 130 adults with this specific 'myeloid-stromal' type of RA. One group will receive the standard drug (methotrexate), while the other gets that drug plus a second one (tofacitinib), to see if the combination controls the disease faster and better.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sun Yat-sen Memorial Hospital
RECRUITINGGuangzhou, Guangdong, 510120, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.